Deferiprone

Product Description

Deferiprone is used to remove excess iron in the body in adults and children 3 years of age and older who have thalassemia (an inherited condition that causes a low number of red blood cells). It is also used to remove excess iron in adults and children 3 years of age and older with sickle cell disease (an inherited blood disease) or other types of anemia (a lower than normal number of red blood cells). Deferiprone is in a class of medications called iron chelators. It works by attaching to iron in the body so that it can be excreted (removed from the body). (Sourced from: https://medlineplus.gov/druginfo/meds/a612016.html)

Mechanisms of Action: Iron Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Latvia | Lithuania | Luxembourg | Malaysia | Morocco | Netherlands | New Zealand | Norway | Pakistan | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: Anemia | Anemia, Sickle Cell | Myelodysplastic Syndrome | Thalassemia | Iron Overload

Known Adverse Events: Abdominal Pain | Back Pain | Headache | Pain Unspecified | Nasopharyngitis | Pharyngitis | Anemia | Anemia, Sickle Cell | Thalassemia | Neutropenia | Arthralgia

Company: ApoPharma
Company Location:
Company CEO:
Additonal Commercial Interests: None